| Robert B Epstein, MD | |
|
825 Ne 10th St, Oupb 5200, Oklahoma City, OK 73104-5417 | |
| (405) 271-8299 | |
| Not Available |
| Full Name | Robert B Epstein |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 825 Ne 10th St, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154390185 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 13450 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert B Epstein, MD 1122 Ne 13th St, Ori 236, Oklahoma City, OK 73117-1039 Ph: (405) 271-1515 | Robert B Epstein, MD 825 Ne 10th St, Oupb 5200, Oklahoma City, OK 73104-5417 Ph: (405) 271-8299 |
News Archive
Elderly patients are often critical towards the meeting with the doctor. Hierarchical structures, time pressure and traditions in the health care sector make these patients and their relatives passive when facing the doctor and his or her position of power. This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
Reverse Medical Corporation today announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device (VRD). The BARREL Vascular Reconstruction Device is designed for use with occlusive devices in the treatment of intracranial bifurcation aneurysms.
The annual incidence rates of primary diagnosed septicemia among active component service members increased nearly 580 percent from 2004 to 2012, according to a new study.
› Verified 2 days ago
Evelyn Lorents, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Patrick Bronson Reeves, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112 Phone: 405-942-5442 Fax: 405-942-6448 | |
Dr. Jake Lee Evans, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Aat 6300, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Metri Haddaden, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young Blvd # 8425, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 410-554-2184 | |
Divya Sharma Divyadarshini, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Dr. Philip Barton Miner, Jr., M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1000 N Lincoln Blvd, Suite 210, Oklahoma City, OK 73104 Phone: 405-271-4644 Fax: 405-271-3296 | |
Gary Lee Worcester, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Ste 400, Oklahoma City, OK 73112 Phone: 405-947-3341 |